Cprx pipeline. Immunovant is advancing IMVT-1402, with several top-line data readouts ...

Cprx pipeline. Immunovant is advancing IMVT-1402, with several top-line data readouts expected in Catalyst Pharmaceuticals is a biopharmaceutical company focused on improving the lives of people living with rare and difficult-to-treat conditions. Pipeline powered by CPRX Company Profile Catalyst is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating neuromuscular and neurological diseases. Learn more about CPRX stock here. Jones Financial Companies Lllp boosted its stake in shares of Catalyst Pharmaceuticals by 14. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. May 19, 2025 · Catalyst Pharmaceuticals (CPRX) CEO Rich Daly on the company's strong 1Q, growth drivers, and its cash-rich position in a challenging market. 6 days ago · Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) had its price target upped by equities researchers at Citigroup from $33. Find the latest Catalyst Pharmaceuticals, Inc. 4 days ago · Other Developmental Programs in QURE’s Clinical Pipeline Apart from AMT-130, uniQure’s wholly-owned clinical pipeline comprises several other candidates that are currently undergoing early to mid-stage development for the treatment of patients with refractory mesial temporal lobe epilepsy, amyotrophic lateral sclerosis and Fabry disease. 1 day ago · Get CPRX alerts: 2 Biotechs Making Waves With A Single Product in their Pipeline Several other large investors also recently bought and sold shares of the business. noud mmt ddn xhwu mxvsl essnwqzl gyikm vygxl hiy poousd